Abstract
● Pharmacogenomic testing has the potential to target medicines more
effectively towards those who will benefit and avoid use in individuals
at risk of harm. ● Implementation of testing into routine practice
across a healthcare system requires consideration of the evidence,
clinical utility, cost-effectiveness, and operational requirements. ● A
national approach to providing pharmacogenomic test recommendations and
centralised commissioning will reduce inequity and duplication, but must
be transparent and evidence based